Thaci, D., K. . Gordon, M. Gooderham, B. Strober, N. Korman, S. Banerjee, S. Banerjee, E. Colston, J. Kim, J. Throup, and A. Morita. “Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Compared With Placebo and Apremilast in Moderate to Severe Psoriasis: Integrated Laboratory Parameter Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials”. SKIN The Journal of Cutaneous Medicine, vol. 5, no. 6, Nov. 2021, p. s37, doi:10.25251/skin.5.supp.37.